Utilization Of Evidence-Based Therapy For The Secondary

Prevention Of Coronary Artery Disease: Predictors And

Impact Of Pharmacist-Initiated Interventions by Kassab, Yaman Walid
  
UTILIZATION OF EVIDENCE-BASED THERAPY FOR THE SECONDARY 
PREVENTION OF CORONARY ARTERY DISEASE: PREDICTORS AND 
IMPACT OF PHARMACIST-INITIATED INTERVENTIONS 
 
 
 
 
 
 
 
 
 
 
 
 
YAMAN WALID KASSAB 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
 
 
July 2013 
 UTILIZATION OF EVIDENCE-BASED THERAPY FOR THE SECONDARY 
PREVENTION OF CORONARY ARTERY DISEASE: PREDICTORS AND 
IMPACT OF PHARMACIST-INITIATED INTERVENTIONS 
 
 
 
 
 
by 
 
 
 
 
YAMAN WALID KASSAB 
 
 
 
 
 
 
 
 
 
 
 
Thesis submitted in fulfillment of the requirements for the degree of Doctor of 
Philosophy 
 
 
 
 
 
 
 
 
 
 
 
 
 
July 2013 
ii 
 
 DEDICATION  
 
 
To the one whose feet Paradise rests on….. 
My beloved mother …. For her prayers, unflagging love, and tremendous sacrifices 
which came with many difficulties and pains. She is always a constant source of 
inspiration and motivation in my life. I learned from her strength how to face life 
strappingly. Her support and love have pulled me throughout my difficult times. 
To my role model… 
My beloved father Proffesor Walid Kassab…who strived and sacrificed to give me the 
best, prepared me to face challenges with faith in concepts, humility and morality. He 
gives me the strength and support by his wonderful, encouraging smile, and always 
motivates me to strive to achieve my goals in life. Thanks father for making me hold 
high your bright name and history. 
To my beloved sisters… 
Alaa Kassab, Mawadah Kassab and Reem Kassab… Thanks for your unconditional 
love that touches my heart…I thank God for such wonderful sisters…forever. 
To my beloved brothers… 
Dr.Mohamed Anas Kassab and Amer Kassab….You kept my spirit up when I found 
it difficult to endure the challenges….you kept me smiling and strong…Thanks for 
your love, passion, and tremendous concern that lifted me up when this thesis seemed 
undoable…I'm proud of you and will remain so, brothers…forever. 
Thank you all for being my family… 
 
 
 
Yaman Walid Kassab 
iii 
 
ACKNOWLEDGEMENT  
 
 
ρuΒt$  ?sθöùÏŠ+Å’þ )Îω /Î$$!« 4 ãt=n‹øμÏ ?sθu.©=ùMà ρu)Î9s‹øμÏ &éΡÏŠ=Ü   دوھ)- 88(  
My guidance depends totally on GOD; I have put my trust in Him. To Him I 
have totally submitted. (Huud – 88) 
 
 
 
First and foremost, I thank Almighty Allah, the most gracious and the most merciful, 
for everything He has given to me. Without His help and blessing, we are unable to do 
anything.  
 
I would like to express my deepest and heartfelt gratitude to my supervisor Professor 
Dr. Yahaya Hassan who has given me the opportunity to pursue this project under his 
supervision. I thank him for his advice, constant support, kind encouragement and 
help. I am really grateful to him and proud to have my degree under his supervision. 
Sincerely thanks to my co-supervisor Professor Dr. Noorizan Abd Aziz. I admire her 
distinguished kindness. May Allah bless them and their family with health and 
happiness.  
 
Special thanks go to my field supervisor Dato Dr. Omar Ismail, Consultant 
Cardiologist &Head Department of Cardiology at Hospital Pulau Penang. In fact, his 
kind permission to conduct this study and recommendation to the Cardiology team to 
cooperate with us were the reasons for this work to be possible.  
 
Grateful thanks also to my hospital pharmacist team (Miss Siew Pul Yee and Miss Kee 
Pek Lian) who helped me to carry out the intervention phase. 
 
My thanks go also to the Clinical Research Center at Hospital Pulau Penang for giving 
me the approval to conduct my study. I am greatly indebted to all the Cardiology team 
members; consultants, Cardiologists, clinical specialists, medical officers, and house 
officers. It is clear that their cooperation was essential for this study. They were 
cooperative, kind, and friendly. 
iv 
 
Last but not least I would like to acknowledge all my dear friends, especially Samer 
Al-Dhalli, June Choon Wai Yee, and Hadeer Akram for their constant support, 
encouragement and love during my stay in Malaysia. You are the best friends I have 
made in over a decade. 
ρu™u#zÅã ó Šyãôθاان &rβÈ  #$:øtpϑô‰ß !¬ ‘u>bÉ #$9øèy≈=nϑÏ⎫⎥š  
And the last our praise is Alhamdulillah to the lord of the worlds 
 
 
Yaman Walid Kassab 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
TABLE OF CONTENT  
 
DEDICATION ............................................................................................................. ii 
ACKNOWLEDGEMENT .......................................................................................... iii 
TABLE OF CONTENT ............................................................................................... v 
LIST OF TABLES ...................................................................................................... xi 
LIST OF FIGURES .................................................................................................. xiii 
LIST OF APPENDICES ............................................................................................ xv 
LIST OF PUBLICATIONS AND COMMUNICATIONS ...................................... xvi 
LIST OF ABBREVIATIONS ................................................................................. xviii 
ABSTRAK ................................................................................................................ xxi 
ABSTRACT ............................................................................................................ xxiv 
CHAPTER 1: INTRODUCTION ................................................................................ 1 
1.1 Coronary Artery Disease: General Background ............................................ 1 
1.1.1 Global Disease Burden .............................................................................. 1 
1.1.2 Coronary Artery Disease in Malaysia ....................................................... 2 
1.2 Acute Coronary Syndrome (ACS) ................................................................ 3 
1.2.1 Definition and Pathophysiology of ACS ................................................... 3 
1.2.2 Spectrum and Clinical Presentation of ACS ............................................. 5 
1.2.3 Risk Factors for CAD ................................................................................ 7 
1.2.3.1 Independent Risk Factors ................................................................ 7 
1.2.3.2 Predisposing Risk Factors .............................................................. 11 
1.2.3.3 Conditional Risk Factors ............................................................... 12 
1.2.3.4 Prevalence Rates of CAD Risk Factors in Malaysia ..................... 14 
1.2.4 Diagnosis of Acute Coronary Syndrome ................................................ 15 
1.2.4.1 Electrocardiogram .......................................................................... 15 
1.2.4.2 Biochemical Cardiac Markers ....................................................... 17 
1.2.4.3 Risk Stratification of ACS Patients ............................................... 20 
1.2.5 Complications of Acute Coronary Syndrome ......................................... 23 
1.2.6 Management of Acute Coronary Syndrome............................................ 23 
1.2.6.1 Anti-ischemic Therapy .................................................................. 24 
1.2.6.2 Antithrombotic Therapy ................................................................ 28 
1.2.6.3 Reperfusion Therapy in Acute Coronary Syndromes .................... 31 
 
vi 
 
CHAPTER 2: LITERATURE REVIEW ................................................................... 33 
2.1 Coronary Artery Disease Prevention ........................................................... 33 
2.1.1 General Measures of CAD Prevention .................................................... 33 
2.2 Secondary Prevention of CAD .................................................................... 34 
2.2.1 Pharmacotherapies in Secondary Prevention of CAD ............................ 35 
2.2.1.1 Antiplatelet Agents ........................................................................ 35 
2.2.1.2 Beta-Blockers ................................................................................ 41 
2.2.1.3 Statins ............................................................................................ 42 
2.2.1.4 Angiotensin Converting Enzyme Inhibitors .................................. 45 
2.2.1.5 Combined Therapy ........................................................................ 47 
2.3 Clinical Practice Guidelines (CPGs) ........................................................... 50 
2.3.1 Impact of CPGs on Patient Outcomes ..................................................... 51 
2.3.2 CPGs and Secondary Prevention of ACS in Clinical Practice ................ 53 
2.3.3 Malaysian Guidelines for Secondary Prevention of ACS ....................... 54 
2.3.3.1 Classification of Recommendations in Malaysian Guidelines ...... 54 
2.3.3.2 Malaysian Guidelines Recommendations ...................................... 55 
2.3.4 Gap Between Guidelines and Clinical Practice....................................... 58 
2.3.5 Compliance to Clinical Practice Guidelines............................................ 60 
2.3.5.1 Awareness-to-Adherence Model ................................................... 60 
2.3.5.2 Cabana Model ................................................................................ 61 
2.3.6 Measuring Compliance to ACS Guidelines ............................................ 63 
2.3.7 Factors that Influence Prescription of Secondary Prevention Therapies 64 
2.3.7.1 Antiplatelet Agents ........................................................................ 64 
2.3.7.2 Beta-Blockers ................................................................................ 65 
2.3.7.3 Statins ............................................................................................ 67 
2.3.7.4 ACEIs ............................................................................................ 68 
2.3.8 Approaches to Improve Physician Adherence to Guidelines .................. 69 
2.3.8.1 Collaborative Pharmacy Medication Review Service ................... 69 
2.3.8.2  Pharmacist initiated Interventions to Promote Behavioral Change 70 
2.4 Patient Adherence to Medication ................................................................ 72 
2.4.1  Definition and Terminology of the Concept of Adherence..................... 73 
2.4.2 Magnitude of the Problem of Poor Adherence........................................ 73 
2.4.3 Factors Affecting Patient Adherence ...................................................... 74 
2.4.3.1 Duration of Treatment ................................................................... 75 
vii 
 
2.4.3.2 Complexity of Regimen ................................................................. 75 
2.4.3.3 Cost of Medication ........................................................................ 76 
2.4.4 Measuring Adherence ............................................................................. 76 
2.4.4.1 Morisky Medication Adherence Scale (MMAS) ........................... 77 
2.5 Problem Statement: Underuse of Preventive Therapies .............................. 79 
2.6 Rationale of the Study ................................................................................. 79 
2.7 Research Hypotheses ................................................................................... 80 
2.8 Objectives of the Study ............................................................................... 81 
2.8.1 General Objectives .................................................................................... 81 
2.8.2 Specific Objectives.................................................................................... 81 
CHAPTER 3: MTERIALS AND METHODS .......................................................... 82 
3.1 Study Design ............................................................................................... 82 
3.2 Study Setting and Duration ......................................................................... 83 
3.3 Study Population ......................................................................................... 84 
3.4 Selection of Subjects ................................................................................... 85 
3.4.1 Inclusion Criteria ..................................................................................... 85 
3.4.2 Exclusion Criteria .................................................................................... 85 
3.5 Sample Size Calculation .............................................................................. 86 
3.6 Ethical Approval of the Study ..................................................................... 86 
3.7 Framework of the Study .............................................................................. 87 
3.7.1 Pre-intervention Phase (Historical Control) ............................................ 87 
3.7.2 Intervention Phase ................................................................................... 93 
3.7.3 Follow-up Phase ...................................................................................... 96 
3.7.3.1 Instruments and Tools .................................................................... 96 
3.7.3.2 Data Collection .............................................................................. 97 
3.8 Outcomes Measurements............................................................................. 99 
3.9 Used Definitions .......................................................................................... 99 
3.9.1 Killip Classification ................................................................................ 99 
3.9.2 New York Heart Association (NYHA) Classification .......................... 100 
3.9.3 Initial Prescribing Rate .......................................................................... 100 
3.9.4 Continuity of Prescribing Rate .............................................................. 100 
3.9.5 Ever Prescribed Rate ............................................................................. 100 
3.9.6 Audit and Feedback ............................................................................... 101 
3.9.7 Reminders ............................................................................................. 101 
viii 
 
3.9.8 Bed Occupency Rate ............................................................................. 101 
3.10 Data Management and Analysis ................................................................ 102 
3.10.1 Data Entry ............................................................................................. 102 
3.10.2 Statistical Analysis ................................................................................ 102 
3.11 Funding of the Study ................................................................................. 105 
CHAPTER 4: RESULTS ......................................................................................... 106 
4.1 Description of Study Patients .................................................................... 107 
4.1.1 Demographic Characteristics of the Patients ........................................ 107 
4.1.2 Medical History ..................................................................................... 109 
4.1.2.1 History of Comorbid Conditions ................................................. 109 
4.1.2.2 History of Cardiovascular Risk Factors ....................................... 110 
4.1.2.3 History of Cardiac Procedures ..................................................... 112 
4.1.2.4 Medication Use Prior to Hospital Admission .............................. 112 
4.1.3 Course of Hospital Episode ................................................................... 113 
4.1.3.1 Clinical Presentations of ACS Patients ........................................ 113 
4.1.3.2 Cardiac Complications at Hospital Admission ............................ 116 
4.1.3.3 In-Hospital Treatment .................................................................. 117 
4.1.4 Prescribing Patterns at Hospital Discharge ........................................... 118 
4.1.4.1 Antiplatelet Agents ...................................................................... 119 
4.1.4.2 Beta-Blockers .............................................................................. 120 
4.1.4.3 ACEIs / ARBs .............................................................................. 121 
4.1.4.4 Statins .......................................................................................... 122 
4.1.4.5 Medications Combinations .......................................................... 123 
4.1.5 Prediction of Evidence-Based Medications use at Hospital Discharge 124 
4.1.5.1 Antiplatelets ................................................................................. 124 
4.1.5.2 Statins .......................................................................................... 126 
4.1.5.3 Beta-Blockers .............................................................................. 126 
4.1.5.4 ACEI / ARBs ............................................................................... 128 
4.1.5.5 Combined Evidence-Based Therapy ........................................... 129 
4.2 Phase II: Intervention Phase ...................................................................... 130 
4.2.1 Types of Recommendations Provided by the Pharmacists ................... 130 
4.2.2 Acceptance of Interventions by Prescribers .......................................... 130 
4.2.3 Impact of the Intervention on Prescribing Practice ............................... 132 
4.2.3.1 Impact on Antiplatelets Prescription ........................................... 132 
ix 
 
4.2.3.2 Impact on ACE-I / ARBs Prescription ........................................ 133 
4.2.3.3 Impact on β-Blockers Prescription .............................................. 133 
4.2.3.4 Impact on Statins Prescription ..................................................... 134 
4.2.3.5 Impact on Prescription of All Four Classes in Combination ....... 134 
4.3 Phase III: Follow-up Study ........................................................................ 136 
4.3.1 Patient Population ................................................................................. 136 
4.3.2 First Follow-up Period .......................................................................... 137 
4.3.2.1 Clinical Outcomes during the First Follow-up Period ................. 137 
4.3.2.2 Prescribing Rates 6 Months Post Discharge ................................ 137 
4.3.2.3 Patients Adherence with Treatment Regimen at 1st  Follow-up .. 138 
4.3.2.4 Non-Adherent Behaviors Measured by MMAS at First TCA ..... 139 
4.3.2.5 Factors Predicting Medication Adherence at First TCA ............. 140 
4.3.3 Second Follow-up Period ...................................................................... 142 
4.3.3.1 Clinical Outcomes during the Second Follow-up Period ............ 142 
4.3.3.2 Prescribing Rates 12 Months Post Discharge .............................. 142 
4.3.3.3 Patients Adherence with Treatment Regimen at 2nd  Follow-up . 143 
4.3.3.4 Non-Adherent Behaviors Measured by MMAS at 2nd  TCA ...... 144 
4.3.3.5 Factors Predicting Medication Adherence at Second TCA ......... 145  
4.3.4 Third Follow-up Period ......................................................................... 147 
4.3.4.1 Clinical Outcomes during the Third Follow-up Period ............... 147 
4.3.4.2 Prescribing Rates 18 Months Post Discharge .............................. 147 
4.3.4.3 Patients’ Adherence with Treatment Regimen at 3rd Follow-up . 148 
4.3.4.4 Non-Adherent Behaviors Measured by MMAS at Third TCA ... 149 
4.3.4.5 Factors Predicting Medication Adherence at Third TCA ............ 150 
4.3.5 Prevalence of Secondary Prevention use during Follow-up Period ...... 151 
4.3.6 Changes in Drug Regimen during Follow-up Period ............................ 152 
4.3.7 Adherence Levels at the Three Time Periods ....................................... 153 
4.3.8 Repeated Measures ANOVA Analysis of Adherence........................... 154 
4.3.9 Long Term Patients’ Adherence to Treatment Regimens ..................... 155 
4.3.10 Factors Predicting Long Term Medication Adherence ......................... 156 
CHAPTER 5: DISCUSSION ................................................................................... 158 
5.1 Description of Study Patients .................................................................... 158 
5.1.1 Patient Demographic and Clinical Characteristics ................................ 159 
5.1.2 Cardiovascular Risk Factors and Comorbid Conditions ....................... 159 
x 
 
5.1.3 ACS Subtypes and Clinical Characteristics upon Admission ............... 161 
5.2 Medications Used Among Patients Prior to Current Coronary Event ....... 162 
5.2.1     Proportion of Medication Combinations used prior to Current Coronary 
Event... ............................................................................................................. 163 
5.3 Prescribing Patterns During Hospitalization and at Discharge ................. 164 
5.3.1 Antiplatelet Agents ................................................................................ 165 
5.3.1.1 Predictors of Antiplatelet Prescription at Discharge ................... 165 
5.3.2 Beta-Blockers ........................................................................................ 166 
5.3.2.1 Predictors of Beta-Blocker Prescription at Discharge ................. 167 
5.3.3 Statins .................................................................................................... 168 
5.3.3.1 Predictors of Statin Prescription at Discharge ............................. 168 
5.3.4 ACEIs / ARBs ....................................................................................... 169 
5.3.4.1 Predictors of ACEI / ARB Prescription at Discharge .................. 169 
5.3.5 Combination of the Four Classes .......................................................... 170 
5.4 Impact of Intervention on Prescribing Practice ......................................... 171 
5.5 Use of Cardioprotective Medications During Follow-up .......................... 174 
5.6 Patient Adherence with Treatment Regimen ............................................. 176 
CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS ........................... 179 
6.1     Conclusions ................................................................................................ 179 
6.2     Strengths of the Study ................................................................................ 180 
6.3     Limitations of the study ............................................................................. 181 
6.4     Recommendations for future work ............................................................ 182 
REFERENCES ......................................................................................................... 185 
APPENDICES ......................................................................................................... 222 
 
xi 
 
LIST OF TABLES 
 
Table number                                      Title Page 
   
Table 1.1  Common Transient ECG Abnormalities in ACS 16 
Table 1.2 TIMI risk score for UA / NSTEMI 22 
Table 1.3 TIMI risk score for STEMI 23 
Table 2.1 Recommended dosages of β-blockers in ACS 56 
Table 2.2 Recommended dosages of ACEIs and ARBs in ACS 58 
Table 3.1 Acute Coronary Syndrome Criteria  84 
Table 4.1  Prior history of both cardiac and non-cardiac related 
comorbidities 
110 
Table 4.2 History of cardiovascular risk factors 111 
Table 4.3 History of cardiac procedures prior to hospital admission  112 
Table 4.4 Drug use prior to hospital admission 113 
Table 4.5 Clinical presentations of control patients by ACS stratum 114 
Table 4.6 Clinical presentations of subjects in the intervention group  115 
Table 4.7 Cardiac complications at hospital admission in both groups 116 
Table 4.8 In-Hospital procedures and medications in both groups 117 
Table 4.9 Predictors of DAT prescription at discharge 125 
Table 4.10 Predictors of statin prescription at discharge 126 
Table 4.11 
Table 4.12 
Table 4.13 
Predictors of beta-blocker prescription at discharge 127 
128 
129 
130 
 
136 
Predictors of ACEI/ARB prescription at discharge 
Predictors of Combined EBT prescription at discharge 
Table 4.14 
 
Table 4.15 
Recommendations provided by the pharmacists in the 
intervention group 
Reasons for not completing the follow up study 
 
 
 
 
xii 
 
Table number Title Page 
   
Table 4.16 Patients’ characteristic according to level of adherence at 
first follow-up 
139 
Table 4.17 Factors predicting medication adherence at first TCA 141 
Table 4.18 Patients’ characteristic according to level of adherence at 
second follow-up 
144 
Table 4.19 Factors predicting medication adherence at second TCA 146 
Table 4.20 Patients’ characteristic according to level of adherence at 
third follow-up 
149 
Table 4.21 Factors predicting medication adherence at third TCA 151 
Table 4.22 Trends in EBM use from hospital discharge to third follow 
up 
152 
Table 4.23 Patients’ characteristic according to long term level of 
adherence 
155 
Table 4.24 Factors predicting long term medication adherence 156 
 
 
 
 
 
xiii 
 
LIST OF FIGURES 
 
Figure number                                   Title Page 
   
Figure 1.1  Biochemical markers in suspected acute coronary syndrome 20 
Figure 3.1 Flow chart of the Pre-intervention phase (Phase I) 92 
Figure 3.2 Flow chart of the Intervention phase (Phase II) 95 
Figure 3.3 Flow chart of the Follow-up study (Phase III) 98 
Figure 4.1 Gender distribution of ACS patients included in the study 107 
Figure 4.2 Age distribution of ACS patients included in the study  107 
Figure 4.3  Ethnic groups of ACS patients included in the study 109 
Figure 4.4 Distribution of presence of cumulative cardiovascular risk 
factors 
111 
Figure 4.5 Prescription rate of antiplatelets at discharge in both groups  119 
Figure 4.6 Prescription rate of beta-blockers at discharge in both groups 121 
Figure 4.7 Prescription rate of ACEI / ARBs at discharge in both groups 122 
Figure 4.8 Prescription rate of Statins at discharge in both groups 123 
Figure 4.9 Types of EBM combinations prescribed at discharge in both 
groups 
124 
Figure 4.10 Acceptance of interventions by prescribers 131 
Figure 4.11 Recommendations accepted by prescribers 131 
Figure 4.12 Impact on Antiplatelets prescription at discharge 132 
Figure 4.13 Impact on ACEI / ARBs prescription at discharge 133 
Figure 4.14 Impact on Beta-blockers prescription at discharge 133 
Figure 4.15 Impact on Statins prescription at discharge 134 
Figure 4.16 Impact on the number of evidence-based medications 
prescribed together at discharge 
135 
Figure 4.17 Prescribing rates at first follow-up visit 138 
 
 
xiv 
 
Figure number                                   Title Page 
   
Figure 4.18  Patients’ responses to question 8 of MMAS at first TCA 140 
Figure 4.19 Prescribing rates at second follow-up visit 143 
Figure 4.20 Patients’ responses to MMAS questions at second TCA 144 
Figure 4.21 Patients’ responses to question 8 of MMAS at second TCA 145 
Figure 4.22 Prescribing rates at third follow-up visit 148 
Figure 4.23 Patients’ responses to MMAS questions at third TCA  149 
Figure 4.24  Patients’ responses to question 8 of MMAS at third TCA 150 
Figure 4.25 Persistence of prescription of EBM throughout the follow-up 
period 
153 
Figure 4.26 Level of adherence across the three consecutive time periods  153 
Figure 4.27 Changes in MMAS scores over the study period 154 
 
xv 
 
LIST OF APPENDICES 
 
Appendix No.                                   Title Page 
   
Appendix 1 Nomogram for the calculation of sample size 222 
Appendix 2 National Institutes of Health Approval for Conducting 
Research in the Ministry of Health 
223 
Appendix 3 Medical Research and Ethics Committee of the Ministry of 
Health letter 
224 
Appendix 4 Investigator's Agreement, Head of Department’s and  
Institutional Approval 
225 
Appendix 5 Informed Consent Form  226 
Appendix 6 Patient Information Sheet  227 
Appendix 7
   
Appendix 8 
Data Collection Form  
Intervention Card 
232 
235 
Appendix 9 Intervention Form 236 
Appendix 10 Confidential Disclosure Agreement for the use of Morisky 
Medication Adherence Scale Bahasa Melayu Version 
(MMAS-BM) 
239 
Appendix 11 English Version of Morisky Medication Adherence Scale  240 
Appendix 12 Bahasa Melayu Version of Morisky Medication Adherence 
Scale 
241 
Appendix 13 Follow-up Form  242 
Appendix 14 Universiti Sains Malaysia: Postgraduate Research Grant 
Scheme (USM-RU-PRGS) 
245 
Appendix 15 Affirmation of Translation of MMAS for ACS Patients 247 
Appendix 16 Affirmation of Editing of Abstract’s Translation (English-
Malay) 
248 
Appendix 17 Certificate of English Editing 249 
Appendix 18 Relevant Original Publications and Communications 250 
 
 
 
   
xvi 
 
LIST OF PUBLICATIONS AND COMMUNICATIONS 
 
Journal Published 
1- Hassan, Y., Kassab, Y., Abd Aziz, N., Akram, H., & Ismail, O. (2013). The 
impact of pharmacist-initiated interventions in improving acute coronary 
syndrome secondary prevention pharmacotherapy prescribing upon discharge. 
Journal of Clinical Pharmacy and Therapeutics, 38(2), 97-100. doi: 
10.1111/jcpt.12027 (IF=2.104). 
 
2- Kassab, Y. W., Hassan, Y., Aziz, N. A., Akram, H., & Ismail, O. (2012). Use 
of evidence-based therapy for the secondary prevention of acute coronary 
syndromes in Malaysian practice. Journal of Evaluation in Clinical Practice, 
doi: 10.1111/j.1365-2753.2012.01894.x (IF=1.508). 
 
3- Kassab, Y., Hassan, Y., Abd Aziz, N., Ismail, O., & AbdulRazzaq, H. (2013). 
Patients’ adherence to secondary prevention pharmacotherapy after acute 
coronary syndromes. International Journal of Clinical Pharmacy, 35(2), 275-
280. doi: 10.1007/s11096-012-9735-y (IF=0.859). 
4- Yaman Walid Kassab, Yahaya Hassan, Noorizan Abd Aziz, Omar Ismail. 
Seventeen-month follow-up of drug utilization for secondary prevention in 
coronary artery disease. International Journal of Pharmacy Teaching & 
Practices 2012, 3(1), 228-231 (ICV=4.29). 
 
Conference Presentations 
1- Y. W. Kassab, Y. Hassan, N. Abd Aziz, H. A. AbdulRazzaq, A. H. Altaie, M. 
F. Najjar, and O. Ismail, Patients’ adherence to secondary prevention 
pharmacotherapy after acute coronary syndromes. Proceeding of the 41st 
European Society of Clinical Pharmacy ESCP Symposium, 28-31 October, 
2012 Barcelona, Spain. 
 
2- Y. W. Kassab, Y. Hassan, N. Abd Aziz, H. A. AbdulRazzaq, A. H. Altaie, M. 
Najjar, and O. Ismail, The impact of pharmacist-initiated interventions in 
improving acute coronary syndrome secondary prevention pharmacotherapy 
prescribing upon discharge. Proceeding of the 41st European Society of 
Clinical Pharmacy ESCP Symposium, 28-31 October, 2012 Barcelona, Spain. 
 
xvii 
 
3- Yaman Walid Kassab, Yahaya Hassan, Noorizan Abd Aziz, Hadeer Akram 
AbdulRazzaq, Omar Ismail. Two years follow-up of drug utilization for 
secondary prevention in coronary artery disease. Proceeding of the 18th Dubai 
International Pharmaceuticals and Technologies Conference and Exhibition 
DUPHAT, 12-14 March, 2012 Dubai UAE.  
4- Kassab Y. W., Hassan Y. , Abd Aziz N. , AbdulRazzaq H. A. , AlKaf M. S., 
Ismail O. Assessment of the Secondary Prevention for Patients with Acute 
Coronary Syndrome in Penang General Hospital, Malaysia. Proceeding of the 
11th Asian Conference on Clinical Pharmacy ACCP, June 24-27, 2011 Manila, 
Philippine.   
  
 
xviii 
 
LIST OF ABBREVIATIONS 
 
 
ACC                       
ACE-I 
ACEP                  
ACS                     
AHA 
ARB                     
AST  
BMI    
BMS                  
CABG                  
CAD                    
CCU                    
CHF                     
CI                        
CK                       
COPD                  
CPGs                   
CRC                     
CRW                    
CVD                    
DALYs 
DAT 
DES 
DM                      
 
American College of Cardiology 
Angiotensin Converting Enzyme Inhibitor 
American College of Emergency Physicians 
Acute Coronary Syndrome 
American Heart Association 
Angiotensin Receptor Blocker 
Aspartate Transaminase 
Body Mass Index 
Bare Metal Stent 
Coronary Artery Bypass Grafting 
Coronary Artery Disease 
Coronary Care Units 
Congestive Heart Failure 
Confidence Interval 
Creatine Kinase 
Chronic Obstructive Pulmonary Disease 
Clinical Practice Guidelines 
Clinical Research Center 
Cardiology Rehabilitation Ward 
Cardiovascular Disease 
Disability-Adjusted Life Years 
Dual Antiplatelet Therapy 
Drug-Eluting Stent 
Diabetes Mellitus 
xix 
 
EBM  
EBT                  
ECG                     
GFR  
GP 
HbA1c 
HDL 
HPP 
IHD     
LBBB                
LDH                    
LDL    
LVD                 
LVEF                  
MI                       
MMAS                
MREC 
NACB 
NHAM  
NO               
NSTEMI              
NYHA                 
OMPN 
OR              
PCI                      
RAAS                 
RCTs    
Evidence Based Medicine 
Evidence Based Therapy 
Electrocardiogram 
Glomerular Filtration Rate 
Glycoprotein 
Glycosylated Hemoglobin A1c 
High-Density Lipoprotein 
Hospital Pulau Penang 
Ischemic Heart Disease 
Left-Bundle Branch Block 
Lactate Dehydrogenase 
Low-Density Lipoprotein 
Left Ventricular Disease 
Left Ventricular Ejection fraction 
Myocardial Infarction 
Morisky Medication Adherence Scale 
Medical Research and Ethics Committee 
National Academy of Clinical Biochemistry 
National Heart Association of Malaysia 
Nitrous Oxide 
Non ST segment Elevation Myocardial Infarction 
New York Heart Association 
Outpatient Medical Progress Notes 
Odds Ratio 
Percutaneous Coronary Intervention 
Renin Angiotensin Aldosterone System 
Randomized Control Trials 
xx 
 
RR    
RRR            
STEMI                 
TIMI                    
TLC                     
UA                       
WHO 
Relative Risk 
Relative Risk Reduction 
ST segment Elevation Myocardial Infarction 
Thrombolysis In Myocardial Infarction 
Therapeutic Lifestyle Changes 
Unstable Angina 
World Health Organization 
 
 
 
 
 
 
xxi 
 
UTILISASI PENGGUNAAN UBAT-UBATAN BERASASKAN BUKTI 
UNTUK PENCEGAHAN PENGULANGAN PENYAKIT ARTERI 
KORONARI: PERAMAL DAN IMPAK INTERVENSI OLEH AHLI 
FARMASI 
 
ABSTRAK 
Sejak beberapa dekad yang lalu, pencegahan pengulangan telah memainkan peranan 
yang semakin penting dalam pengurusan penyakit arteri koronari. Antara ubat-ubatan 
untuk pencegahan pengulangan jangka panjang adalah antiplatelet, penghalang-β, 
penghalang enzim angiotensin (ACEI) dan statin, yang telah terbukti amat berkesan 
dalam mengurangkan morbiditi dan mortaliti dalam kalangan pesakit koronari. Garis 
panduan perubatan di Malaysia menekankan penggunaan ubat-ubatan berasaskan 
bukti (evidence-based medicine, EBM) secara berterusan untuk rawatan jangka 
panjang selepas kejadian koronari akut (pencegahan pengulangan). Walaupun 
cadangan garis panduan telah diwujudkan, namun kajian melaporkan praktis EBM 
yang rendah pada pesakit sindrom koronari akut (acute coronary syndrome, ACS). 
Objektif utama kajian ini adalah untuk: (1) menentukan praktis EBM selepas  kejadian 
koronari akut dan penggunaan berterusan dalam penjagaan pesakit luar, (2) menilai 
kesan intervensi yang dimulakan oleh ahli farmasi untuk meningkatkan penggunaan 
ubat pencegahan pengulangan semasa discaj (3) menilai kepatuhan pesakit terhadap 
EBM pada purata dua tahun selepas discaj, dan (4) menyiasat korelasi antara 
ketidakpatuhan pesakit dan peramal lain. Kajian ini menggunakan metodologi 
perbandingan intervensi dalam tiga fasa: pra-intervensi, intervensi, dan peringkat 
susulan. Dalam fasa pr-intervensi, audit retrospektif dijalankan dan suatu sampel 
rawak daripada rekod perubatan pesakit ACS yang dimasukkan ke Hospital Pulau 
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Pinang dalam tempoh  Januari 2008 hingga Januari 2010 dipilih sebagai kumpulan 
kawalan. Fasa intervensi dijalankan dari Mac hingga September 2010. Dua orang ahli 
farmasi hospital, yang juga merupakan ahli dalam pasukan kardiologi memberikan 
perkhidmatan “ulasan ubat farmasi kolaboratif”. Perkhidmatan yang disediakan sebaik 
mungkin melaksanakan semua intervensi dalam usaha meningkatkan kepatuhan 
kepada garis panduan bagi ACS. Ia terdiri daripada audit dan maklum balas.  pengingat 
garis panduan diletakkan dalam rekod pesakit dan perbincangan dengan doktor pada 
setiap rondaan perubatan harian. Semasa fasa susulan, semua pesakit dalam kumpulan 
intervensi ditentukan dalam tempoh dua tahun untuk menyiasat preskripsi jangka 
panjang EBM dan kepatuhan pesakit terhadap terapi mereka. Sejumlah 380 orang 
pesakit telah dipilih secara rawak dengan 190 pesakit dalam setiap kumpulan. Pesakit 
dalam kedua-dua kumpulan dirawat oleh pasukan doktor yang sama dan dipadankan. 
Audit yang dijalankan dalam fasa pertama menunjukkan penggunaan EBM yang 
rendah. Kadar preskripsi discaj bagi gabungan EBM hanya 42.6%. Semasa fasa 
intervensi, sebanyak 72 intervensi telah dibuat oleh ahli farmasi, kes intervensi 
memulakan ubat adalah paling kerap (59.7%), inin diikuti dengan cadangan untuk 
menukar kepada ubat yang lain (23.6%) dan pengoptimuman dos ubat (16.6%).  
Daripada cadangan yang diutarakan, 65.3% diterima, 6.9% diubah suai, dan 27.8% 
ditolak. Majoriti intervensi yang diterima adalah dengan penghalang-β (38.46%) 
diikuti dengan ACEIs (28.8%) dan statin (21.15%). Intervensi secara signifikannya 
meningkatkan kadar preskripsi penghalang-β (daripada 75.8% kepada 84.2%), ACEIs 
(daripada 65.3% kepada 74.7%), dan statin (daripada 91.6% kepada 98.4%). Di 
samping itu, kemungkinan discaj dengan regimen daripada 4 kelas ubat-ubatan 
pencegahan pengulangan dalam kumpulan intervensi adalah 2.2 kali lebih tinggi 
daripada kumpulan kawalan. Berdasarkan kepatuhan ubat, dilaporkan bahawa majoriti 
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pesakit mempunyai kepatuhan sama ada sederhana atau rendah sepanjang tempoh 
susulan dan hanya sebahagian kecil mempunyai kepatuhan yang tinggi. Tambahan 
pula, terdapat penurunan yang signifikan dalam skor “Morisky Medication Adherence 
Scale” (MMAS) merentasi tempoh tiga kali susulan berturut-turut. Pesakit lelaki 
dilaporkan mempunyai kepatuhan yang lebih tinggi berbanding dengan pesakit 
perempuan. Pesakit yang bekerja dilaporkan mempunyai kepatuhan lebih tinggi 
daripada yang tidak bekerja. Pesakit STEMI dilaporkan mempunyai kepatuhan 
tertinggi, diikuti oleh pesakit NSTEMI dan UA. Pesakit dengan pelbagai ko-morbiditi 
(≥ 3) atau pelbagai ubat-ubatan (≥ 5) dilaporkan mempunyai kepatuhan yang sangat 
rendah. Kesimpulannya, kajian ini menunjukkan bahawa intervensi yang dimulakan 
ahli farmasi secara signifikan meningkatkan kadar preskripsi discaj untuk terapi 
pencegahan pengulangan ACS. Kami juga merumuskan bahawa terdapat masalah 
ketidakpatuhan kepada ubat-ubatan dalam kalangan pesakit ACS di Malaysia. 
Tambahan pula, kajian ini menunjukkan bahawa pesakit yang terdiri daripada warga 
tua, tidak bekerja, pesakit dengan ubat-ubatan dan pelbagai komorbiditi adalah 
golongan yang paling memerlukan perhatian doktor untuk meningkatkan kepatuhan 
mereka terhadap regimen ubat.   
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UTILIZATION OF EVIDENCE-BASED THERAPY FOR THE SECONDARY 
PREVENTION OF CORONARY ARTERY DISEASE: PREDICTORS AND 
IMPACT OF PHARMACIST-INITIATED INTERVENTIONS 
 
ABSTRACT 
Over the past decades, secondary prevention has played a more and more important 
role in coronary artery disease management. Among the medications for long-term 
secondary prevention, antiplatelets, β-blockers, angiotensin-converting enzyme 
inhibitors (ACEIs), and statins were proven to be highly effective in reducing 
morbidity and mortality in coronary patients. Malaysian guidelines emphasize the 
continuous use of these evidence-based medications (EBMs) for long-term treatment 
after an acute coronary event. Despite the guideline recommendations, studies have 
reported an underuse of these EBMs in ACS patients. The main objectives of the 
current study were to: (1) quantify the prescription of EBMs at discharge following an 
acute coronary event and ongoing use in ambulatory care, (2) evaluate the impact of 
pharmacist-initiated interventions on improving the prescribing trend of secondary 
preventive therapies upon discharge, (3) evaluate patients’ adherence to EBMs at an 
average of two years after discharge, and (4) investigate the relationship between 
patients’ non-adherence and various predictors. This study adopted an interventional 
comparative methodology with three phases: pre-intervention, intervention, and 
follow-up phases. In the pre-intervention phase, a retrospective audit was conducted 
and a random sample of medical records pertaining to ACS patients admitted to 
Hospital Pulau Pinang during the period from January 2008 to January 2010 was 
chosen as the control group. The intervention phase was carried out from March to 
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September 2010. Two hospital pharmacists who were already apart of the cardiology 
team provided the “collaborative pharmacy medication review” service. The service 
implemented all possible interventions that might improve compliance with Malaysian 
guidelines for ACS. It consisted of audit and feedback, guideline reminders placed in 
patients’ records, and discussion with every single prescriber during daily medical 
rounds. During the follow-up phase, all patients in the intervention group were 
followed up over a two year period to investigate the long term prescribing of EBMs 
as well as long term patients’ adherence to their therapy. A total of 380 patients were 
randomly selected with 190 patients in each group. Patients in both groups were treated 
by the same team of physicians and matched.  
The audit conducted in the first phase showed substantial underuse of these EBMs. 
The discharge prescription rate of combined EBMs was only 42.6%. During 
intervention phase, a total of 72 interventions were made by the pharmacists, of which 
drug initiation was most common (59.7%) followed by recommendations to change to 
another medication (23.6%) and optimization of medication dosing (16.6%). The 
prescribers accepted 65.3% of the recommendations as suggested and 6.9% with some 
modification and rejected 27.8% of the recommendations. Majority of accepted 
interventions were with β-blockers (38.46%) followed by those with ACEIs (28.8%) 
and statins (21.15%). The interventions significantly increase the prescription rates of 
β-blockers (from 75.8% to 84.2%), ACE-Is (from 65.3% to 74.7%), as well as statins 
(from 91.6% to 98.4%). In addition, the odds of being discharged on a regimen of 4 
classes of secondary preventive medications in the intervention group were 2.2 times 
higher than the control group. Regarding medication adherence, majority of patients 
reported either medium or low adherence across the follow-up period with only small 
portion reported high adherence. Furthermore, there was a significant decrease in 
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MMAS scores across the three consecutive time periods. Male patients reported higher 
adherence than females. Employed patients reported higher adherence than 
unemployed. STEMI patients reported the highest adherent behavior, followed by 
NSTEMI and UA patients. Patients with multiple co-morbidities (≥ 3) or those who 
were prescribed multiple medications (≥ 5) reported significantly poorer adherence. 
In conclusion this study has shown that pharmacist-initiated interventions can 
significantly increase the discharge prescription rates of ACS secondary preventive 
therapies. We also concluded that there is a problem of non-adherence to medications 
among patients with ACS in Malaysia. Furthermore, this study demonstrated that 
elderly, unemployed, patients with multiple medications and comorbidities were most 
in need for physicians’ attention to improve their adherence to medication regimens. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Coronary Artery Disease: General Background 
Cardiovascular disease (CVD) is recognized as a major global health problem. 
It affects every aspect of a patient’s life, including quality of life, employment, and 
even causing premature death (Mathers & Loncar, 2006). 
The term ‘CVD’ includes a wide variety of disorders, such as diseases of the 
heart muscle, the vascular system supplying the heart, the brain, and other vital organs. 
Although the term can include any disease that influences the cardiovascular system, 
in practice it usually refers to those involving atherosclerosis. 
1.1.1 Global Disease Burden 
CVD is the single most common cause of mortality worldwide and is expected 
to remain so for the next 20 years (Mathers & Loncar, 2006). The World Health 
Organization (WHO) estimates that 17.3 million people died from CVD in 2008, 
accounting for 30% of all global deaths, and projects that this number will rise to 23.6 
million by 2030 (WHO, 2011). 
Within CVD, coronary artery disease (CAD) is the most prevalent cardiac 
disorder. Due to its growing incidence across the world, CAD is considered an 
epidemic (WHO, 2009). It is estimated that 7.2 million people die from CAD annually, 
and this number is projected to increase to 11.1 million by 2020. Further, according to 
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the Global Burden of Disease estimates, CVD is responsible for 151 billion disability-
adjusted life years (DALYs), representing 10% of the global disease burden, of which 
62 billion is due to CAD (WHO, 2011). 
1.1.2 Coronary Artery Disease in Malaysia 
Malaysia is a multi-ethnic country with a population consisting of Malays, 
Chinese, Indians, and several other ethnicities. In 2010, the population of Malaysia 
was estimated at 28.3 million (Department of Statistics Malaysia, 2010).  
Under the Ninth Malaysia Plan, CVD was documented as one of the top-eight 
diseases for priority research, as it recognized as becoming a major national health 
problem. Based on records of government hospital admissions and deaths, CAD has 
been the leading cause of admission and non-accidental death for the last 10 years 
(MOH-Malaysia, 2008).  
In 2006, there were a total of 31,186 admissions to the 73 coronary care units in 
Malaysia, of which 12,534 admissions were due to acute coronary syndrome (ACS), a 
manifestation of CAD. The incidence of ACS admission in 2006 was therefore 47.1 
per 100,000 population. Assuming half of all CAD patients first present with ACS and 
only half are admitted to the coronary care unit, with 1/3 dying before reaching 
hospital, a rough estimate of the incidence of CAD in Malaysia is 141 per 100,000 
population (Wan Ahmad et al., 2011). 
In 2004, a study on disease burden in Malaysia showed that CAD is the leading 
cause (9.8%) of disability-adjusted life years, accounting for 63% in men and 64% in 
women (WHO-Malaysia, 2009).  
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Further, Health Facts 2009 report showed that the leading causes of death in 
Ministry of Health hospitals were heart diseases and pulmonary circulation diseases 
(16.5%) (MOH-Malaysia, 2010). Additionally, the third-quarter 2010 Penang 
Statistical Report showed that CAD is the second main cause of mortality in Penang 
government hospitals, with 400 (14.8%) deaths attributed to this cause in 2009 (SERI, 
2010). 
1.2 Acute Coronary Syndrome (ACS)  
1.2.1 Definition and Pathophysiology of ACS 
The pathogenesis that underlies most clinical manifestations of CAD is now 
known to be a complex inflammatory process called coronary atherosclerosis (Libby 
& Theroux, 2005). This process is slow and insidious and usually starts early in life, 
although often not manifesting clinically until the age of 40 and beyond. The earliest 
and key event in the development of atherosclerosis is endothelial dysfunction (Sitia 
et al., 2010). 
A number of factors, mechanical shear stresses, biochemical abnormalities, 
immunological factors, inflammation, age, male gender, obesity, and genetic 
alteration, directly contribute to the development and progression of endothelial 
“injury” or dysfunction and atherosclerosis (Falk, 2006). 
The vascular endothelium, a selective lipoprotein-permeable barrier that 
separates the blood from vascular smooth muscle of the artery wall, is capable of a 
wide range of metabolic functions. It regulates anti-inflammatory, mitogenic, and 
contractile activities of the vessel wall, as well as the hemostatic process within the 
vessel lumen. Furthermore, the endothelium acts as a protective surface for the artery 
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wall, stimulates vascular smooth muscle relaxation, and inhibits thrombogenesis and 
atherosclerotic plaque formation (Bonetti, Lerman, & Lerman, 2003). 
Impaired endothelial function increases permeability of the endothelium to low-
density lipoprotein cholesterol (LDL-C) and inflammatory cells, and hence promotes 
their migration and infiltration in the sub-intimal vessel wall. This may lead to 
formation of fatty streaks in the coronary arteries and eventually to atherosclerotic 
plaques (Libby, 2001). Atheromatous plaques are mainly composed of: (1) connective 
tissue extracellular matrix, including collagen, proteoglycans, and fibronectin elastic 
fibers; (2) lipids, like crystalline cholesterol, cholesteryl esters, and phospholipids; (3) 
inflammatory cells such as monocyte-derived macrophages, T-lymphocytes; (4) 
smooth muscle cells; (5) thrombotic material with platelets and fibrin deposition; and 
(6) calcium deposits (Fuster, Moreno, Fayad, Corti, & Badimon, 2005). 
Coronary plaques are constantly stressed by a variety of biochemical, 
mechanical and hemodynamic forces that may precipitate or “trigger” disruption or 
erosion of vulnerable plaques. Following plaque disruption, thrombogenic contents of 
the plaque are exposed to blood elements and trigger platelet aggregation, activation 
of the coagulation system, and ultimately thrombus formation (a clot) on the surface 
of the ruptured plaque. Such rapid coronary thrombosis may result in complete or 
partial occlusion, leading to clinical manifestation of ACS (Fuster et al., 2005). 
ACS refers to a range of severe cardiac presentations which differ in degree, 
duration, and acuteness of coronary occlusion, and includes unstable angina (UA), 
non-ST-segment-elevation myocardial infarction (NSTEMI), and ST-segment-
elevation myocardial infarction (STEMI). 
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1.2.2 Spectrum and Clinical Presentation of ACS 
Although the term ACS is used collectively to describe UA, NSTEMI, and 
STEMI, the pathophysiology and clinical presentations of each differ, as do their 
treatments. The degree of coronary artery occlusion significantly correlates with 
presenting symptoms and with variations in electrocardiogram (ECG) findings and 
cardiac marker values. However, midline anterior chest discomfort continues to be the 
primary symptom of ACS. 
UA and NSTEMI are considered closely related conditions in which the 
coronary artery stenosis is non-occlusive. The subgroup of UA / NSTEMI, which is 
also known as non-ST-segment-elevation (non-STE) ACS, defines the phase of 
symptomatic CAD which occurs after stable angina. Angina is considered unstable if 
it occurs for the first time, at rest, or accelerates in frequency or severity. 
NSTEMI presentation is similar to that of UA, but differs in that ischemia is 
severe enough to cause sufficient myocardial damage, resulting in the release of 
detectable quantities of biochemical markers in the bloodstream from necrotic 
myocytes (Anderson et al., 2007; Bassand et al., 2007). 
Chest pain associated with NSTEMI tends to be more persistent and more severe 
than that associated with UA. In both conditions, the frequency and intensity of pain 
may increase if not relieved by rest, nitroglycerin, or both, and may last longer than 15 
minutes. Chest discomfort may radiate to the shoulder, down the left arm, to the back, 
or to the jaw. Other symptoms that may accompany chest discomfort include nausea, 
vomiting, diaphoresis, and shortness of breath. (Comeau, Jensen, & Burton, 2006).  
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In STEMI, which represents 30–45% of all ACS cases, there is myocardial 
necrosis following acute total coronary occlusion (Afolabi, Novaro, Pinski, Fromkin, 
& Bush, 2007). STEMI presentation is similar to that of UA/NSTEMI, but differs with 
persistent abnormalities on ECG (STE) and positive biomarkers such as troponin and 
creatine kinase–myocardial band (CK-MB) (Lloyd-Jones et al., 2010). 
Many patients with myocardial infarction (MI) present with atypical symptoms, 
such as dyspnea, nausea, diaphoresis, syncope, or malaise. When these “atypical 
symptoms” are present without chest pain, they are known as “angina equivalents” 
(Anderson et al., 2011).  Other patients may show no symptoms of MI (silent 
ischemia). A large, prospective, observational study of over 400,000 patients with 
confirmed MI showed that 33% did not have chest pain on presentation in hospital. 
Patients without pain tended to be older, diabetic, women, and those with prior heart 
failure (Canto et al., 2000). In another smaller study, only 53% of patients with MI had 
a chief complaint of chest pain. Shortness of breath was the complaint in 17%, cardiac 
arrest in 7%, and dizziness/weakness/syncope in 4% (Gupta, Tabas, & Kohn, 2002). 
Unfortunately, establishing diagnosis is more difficult in patients with atypical 
presentation, resulting in poorer outcomes. In addition, these patients are less likely to 
receive recommended therapies known to reduce the risk of mortality (i.e. aspirin, 
beta-blockers, heparin, thrombolysis, or primary angioplasty) (Dorsch et al., 2001). 
The second National Registry of Myocardial Infarction (NRMI-2) study in the United 
States showed that MI patients without chest pain had higher in-hospital mortality 
compared to those with chest pain (23% vs. 9%, respectively) (Canto et al., 2000). 
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1.2.3 Risk Factors for CAD 
CAD is multifactorial in origin, giving rise to the risk-factor concept. Numerous 
epidemiological studies across the world have identified a large number of risk factors 
for CAD (Grundy et al., 2002). These risk factors can be classified into three broad 
categories: independent, predisposing, and conditional. 
1.2.3.1 Independent Risk Factors  
The presence of independent risk factors is of major importance in determining 
CAD occurrence and severity. The Framingham Heart Study showed that these risk 
factors are additive in their predictive value when combined. Accordingly, an 
individual’s global risk for CAD can be estimated by summing the risk imparted by 
each of the independent risk factors. These include the following: 
1.2.3.1 (a) Cigarette Smoking 
The Framingham Heart Study was among the first to evaluate the relationship 
between cigarette smoking and CAD. It examined the level of association separately 
in men and women, the effect of smoking duration, and the impact of smoking 
cessation. This study identified cigarette smoking as one of the leading contributors to 
CAD (Carl, 1989).   
The relationship between smoking and CAD risk is dose dependent and is 
observed among both men and women. Risk for CAD is increased by about 1.8 times 
in active smokers and by about 1.3 times in those exposed to passive or environmental 
smoke. In addition, heavy smoking (> 40 cigarettes per day) was found to almost 
double cardiovascular and overall mortality in those aged less than 65 years. Beyond 
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the age of 65, neither significant nor substantial gradients of risk could be 
demonstrated in either sex for cardiovascular morbidity (William, 1981). 
The direct harmful effects of cigarette smoke to patients with angina include (1) 
rise in blood pressure and heart rate due to nicotine, which increases myocardial 
oxygen consumption, (2) impairment in oxygen delivery to the heart as a result of 
carboxyhemoglobin generation from carbon monoxide inhalation in smoke, (3) the 
negative inotropic effect of carboxyhemoglobin, (4) increased platelet stickiness and 
aggregation caused by carboxyhemoglobin, resulting in thrombotic tendencies, (5) 
lowered threshold for ventricular fibrillation during episodes of ischemia, owing to 
carboxyhemoglobin, and (6) impaired endothelial function (Freund, Belanger, 
D'Agostino, & Kannel, 1993; Ockene & Miller, 1997; William, 1981). 
Observational studies estimate that quitting smoking decreases the risk of all-
cause mortality among patients with CAD by almost 50%. Furthermore, 
approximately 40% of the increased risk is removed within 5 years of quitting, even 
though it takes several more years of non-smoking to reach the “normal” risk level for 
heart disease of those who have never smoked (Critchley & Capewell, 2003; 
O'Donnell & Elosua, 2008).  
1.2.3.1 (b) Hypertension 
The relationship between blood pressure and CAD incidence is examined in 
many observational cohort studies. The Global Burden of Disease study estimates that 
about 47% of all CAD is attributable to elevated blood pressure (Lawes, Hoorn, & 
Rodgers, 2008). In addition, epidemiological analyses show that higher risk for 
cardiovascular events and mortality begins at a blood pressure >115/75 mm Hg in the 
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general population, and doubles for every subsequent 20-mm Hg systolic or 10-mm 
Hg diastolic increase (Buse et al., 2007; Rosendorff et al., 2007). 
1.2.3.1 (c) Hypercholesterolemia 
Hypercholesterolemia has long been recognized as a significant risk factor for 
CAD. The Framingham Heart Study, the Multiple Risk Factor Intervention Trial 
(MRFIT), and the Lipid Research Clinics Trial found a direct relation between levels 
of LDL-C (or total cholesterol) and the rate of new-onset CAD in both men and women 
who were initially free of CAD. The same relationship holds for recurrent coronary 
events in people with established CAD (Castelli, 1988; Gotto, 1997b; Rifkind, 1984). 
Furthermore, any LDL-C above 100 mg/dL appeared to be atherogenic (Grundy et al., 
2002). 
Strong epidemiological evidence implies benefit from lowering LDL-C. A 
recent meta-analysis of 14 randomised trials of statins with 90,056 participants showed 
that lowering LDL-C by 1 mmol/L reduces CVD events by 21% and total mortality by 
12%, regardless of baseline risk (Cholesterol Treatment Trialists' Collaborators, 2005). 
However, epidemiological studies have found high-density lipoprotein 
cholesterol (HDL-C) to be an independent predictor of cardiovascular risk. High levels 
of HDL-C are considered protective, whereas lower levels are associated with 
increased risk. Epidemiological data signify that a 1% reduction in HDL-C is 
associated with a 2–3% increase in CAD risk (Cooper et al., 2008; Nam, Kannel, & 
Dagostino, 2006). 
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1.2.3.1 (d) Diabetes 
Diabetes is considered a powerful contributing factor in all forms of CVD. 
Epidemiological studies show that higher risk for cardiovascular events begins at 
glycosylated hemoglobin A1c (HbA1c) above 6.2%, the upper range of normal values, 
and each 1% rise in HbA1c is associated with a 15% and 18% increase in the relative 
risk of CVD among patients with type I and type II diabetes mellitus, respectively 
(Buse et al., 2007).  
The increase in risk attributed to hyperglycemia per se is independent of the 
overweight/obesity and dyslipidemia usually noticed in patients with diabetes. 
Furthermore, the mortality rate in diabetic patients with established CAD is much 
higher than in non-diabetic patients (Grundy et al., 2002).  
Glycemic control undoubtedly decreases the risk of macro-vascular 
complications in diabetic patients; nevertheless, currently there are no clinical trials on 
glycemic intervention showing clear-cut evidence that glucose lowering diminishes 
the risk of CVD (Buyken, von Eckardstein, Schulte, Cullen, & Assmann, 2007).  
1.2.3.1 (e) Advancing Age 
Risk for ischemic heart disease rises with advancing age in both men and 
women. The main reason for this is that age is a reflection of progressive accumulation 
of coronary atherosclerosis, which in turn reflects cumulative exposure to atherogenic 
risk factors (Grundy, 1999). Increased age-specific risk becomes most clinically 
significant in men in their mid-40s and in women around the age of menopause. At 
any given age, women are at lower risk for coronary disease than men. Risk in women 
lags behind that of men by approximately 10 to 15 years (Wilson et al., 1998). 
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1.2.3.2 Predisposing Risk Factors 
Predisposing risk factors intensify the risk associated with causal (independent) 
risk factors (Grundy, Pasternak, Greenland, Smith, & Fuster, 1999). These risk factors 
are described in the following subsections. 
1.2.3.2 (a) Obesity 
Obesity has reached epidemic proportions globally. The WHO estimates that in 
2008, more than 1.5 billion adults aged 20 years and above were overweight (BMI ≥ 
25). Of these, over 200 million men and nearly 300 million women – approximately 
10% of adults – were obese (BMI ≥ 30) (WHO, 2008). 
Furthermore, overweight and obesity now rank as the fifth principal risk for 
mortality worldwide; annually more than 2.8 million adults die from complications 
associated with overweight and obesity. Moreover, 44% of the diabetes burden and 
23% of CAD are attributable to overweight and obesity (WHO, 2009). 
Obesity was classified by the American Heart Association (AHA) as a major, 
modifiable risk factor for CVD. Risk is particularly raised when obesity has a 
predominant abdominal fat distribution (Grundy et al., 2002). Abdominal obesity is 
defined by a waist circumference greater than 102 cm in men or 88 cm in women. 
Obesity, especially abdominal obesity, raises blood pressure and total 
cholesterol levels, lowers HDL-C levels, and even increases the risk of type II diabetes 
(Hubert, Feinleib, McNamara, & Castelli, 1983). In addition, some studies show that 
abdominal obesity is related to endothelial dysfunction, a marker of CAD (Carr & 
Brunzell, 2004; Wessel et al., 2004). 
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1.2.3.2 (b) Physical Inactivity 
Physical inactivity is also defined by the AHA as a major, modifiable risk factor. 
Many studies, including the Framingham Heart Study, show that physical inactivity 
increases the risk for CAD (Grundy et al., 1999); furthermore, some studies estimate 
the increase in CAD risk to be about 1.5 times (Lloyd-Jones et al., 2010). 
1.2.3.2 (c) Family History of Premature CAD 
A positive family history of premature CAD is a major risk factor for CAD. 
Relative risk for CAD in first-degree relatives (parent, sibling, or offspring) has been 
reported in several studies to be from 2 to 12 times that of the general population 
(Grundy et al., 2002). Risk rises with the number of affected first-degree relatives and 
at earlier ages of onset in the probands. Among first-degree relatives, it seems that 
siblings of probands have the greatest relative risk (Pohjola-Sintonen, Rissanen, 
Liskola, & Luomanmaki, 1998). 
1.2.3.3 Conditional Risk Factors 
Conditional risk factors are associated with higher risk for CAD, even though 
their causative and independent contributions to CAD remain to be documented 
(Grundy et al., 1999). These factors are described in the following subsections. 
1.2.3.3 (a) Homocysteine 
Homocysteine is a sulfur-containing amino acid derived from conversion of 
methionine to cysteine (Kardesoglu, Uz, Isilak, & Cebeci, 2010). Elevated levels of 
homocysteine most likely result from deficiencies in some B vitamins and several rare 
hereditary diseases, or they can be drug-induced (Ntaios, Savopoulos, Grekas, & 
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Hatzitolios, 2009). Evidence has accumulated to support the concept that elevated 
plasma homocysteine is a strong predictor for the incidence of and mortality from 
atherosclerosis, CVD, and ischemic stroke, and this graded association is noted to be 
independent of other traditional risk factors (Bostom et al., 1999; Tanne et al., 2003). 
Elevation of serum homocysteine is associated with higher risk for CAD. The 
mechanism underlying the relation between homocysteine and CAD is not yet fully 
understood, even though patients with severe hereditary forms of hyper-
homocysteinemia have premature vascular damage and atherosclerosis (Giles, Croft, 
Greenlund, Ford, & Kittner, 2000).  
1.2.3.3 (b) Elevated Lipoprotein (a) 
Lipoprotein (a) (LP (a)), is an LDL-like particle in which apolipoprotein B-100 
is covalently bound to glycoprotein apoprotein (a). Apoprotein (a) has a similar 
structure to plasminogen but does not have its enzymatic action. Therefore, it can 
inhibit fibrinolysis by binding to the catalytic complex of plasminogen, tissue 
plasminogen activator, and fibrin, leading to thrombosis (Marcovina & Koschinsky, 
2003).  
Several studies establish a significant correlation between serum lipoprotein (a) 
levels and CAD risk (Grundy et al., 1999). A meta-analysis of 27 prospective studies 
supports the proposition that elevated LP (a) levels have a significant and independent 
predictive power for CAD risk (Danesh, Collins, & Peto, 2000). In addition, 
concomitant elevations of LP (a) and LDL-C are reported to have synergy in rising 
risk in both men and women with dyslipidemia (Grundy et al., 2002). 
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1.2.3.3 (c) C-Reactive Protein (CRP) 
A wealth of evidence now supports the role of chronic inflammatory process in 
the development and progression of atherosclerosis (St-Pierre et al., 2005). 
Inflammatory processes may contribute to plaque instability and thrombosis, thus 
increasing the risk of ACS (Drakopoulou et al., 2009). Several studies suggest that 
inflammatory markers, such as C-reactive protein (CRP), have predictive value for 
future coronary events (Fichtlscherer, Heeschen, & Zeiher, 2004).  
CRP is an acute-phase plasma protein synthesized by the liver and has been 
demonstrated to reflect the degree of coronary inflammation and provide unique 
information unrelated to biomarkers of myocyte necrosis and hemodynamic stress in 
patients with ACS. High-sensitivity test appears to be the preferred method for 
measurement of CRP; plasma high-sensitivity C-reactive protein concentrations 
greater than 3 mg/L appear to be an independent predictor of risk for developing ACS 
in patients without known CAD (Drakopoulou et al., 2009).  
1.2.3.4 Prevalence Rates of CAD Risk Factors in Malaysia 
In 2008, a non-communicable diseases survey was conducted to provide 
surveillance baseline information to assess the extent of non-communicable disease 
risk factors in Malaysia. The survey gathered a wide range of data on the socio-
demographic status and non-communicable disease risk factors of people aged 
between 25 and 64 years. The following prevalence rates were found: 34.7% had 
elevated blood pressure; 10.5% had high blood glucose; 53.5% had raised cholesterol 
levels; 44.2% were overweight; 14.0% were obese; 48.6% had abdominal obesity; 
21.5% were current smokers; 60.5% were physically inactive; 12.2% consumed 
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alcohol; and 18.1%, 29.7%, 28.4%, 13.8% and 7.0%, had one, two, three, four and 
more than four non-communicable disease risk factors, respectively (WHO-Malaysia, 
2011). 
1.2.4 Diagnosis of Acute Coronary Syndrome 
Differentiating ACS from non-cardiac chest pain is the main diagnostic 
challenge. Initial assessment requires a detailed case history (including risk factor 
analysis), physical examination, an ECG, and cardiac markers measurement (cardiac 
troponin in particular). Therapeutic decision making is based on this approach. 
1.2.4.1 Electrocardiogram 
ECG is an important and central tool to evaluate a patient with suspected ACS. 
Clear evidence exists to support the association between a delay in management and 
death in STEMI (Weaver et al., 1993). Therefore, a 12-lead ECG should be performed 
rapidly on all patients with a presentation consistent with ACS. According to the 
AHA/ACC guidelines for patients with chest pain, an initial screening ECG should be 
done and interpreted within 10 minutes of arrival at an emergency department 
(Kushner et al., 2009). The main ECG findings indicative of myocardial ischemia or 
infarction are STE, ST-segment depression, and T-wave inversion (Table 1.1). 
Sub-endocardial ischemia results in ST-segment depressions and/or T-wave 
flattening or inversions, while severe transient transmural ischemia can result in STEs 
(Amsterdam, Diercks, & Kirk, 2009). Existing Q waves are not indicative of acute 
ischemia but do strongly suggest prior MI and the existence of underlying CAD 
(Anderson et al., 2007). 
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Table 1.1. Common Transient ECG Abnormalities in ACS 
Normal Sub-endocardial ischemia Transmural Ischemia 
 
 
 
 
  
 
 
ST depression             ST depression                     T wave   
  (Horizontal)              (Down sloping)                  inversion 
 
 
 
 
 
       ST elevation             
(Anderson et al., 2007). 
Unfortunately, ECG is a fairly specific but relatively insensitive test for the 
presence of myocardial ischemia; this could be attributable to the fact that some parts 
of the heart are more “electrically silent” than others, hence myocardial ischemia may 
not be detected on a surface ECG. In spite of the prognostic value of the initial ECG, 
a normal or non-specific ECG does not entirely exclude the possibility of ACS. Slater 
and colleagues evaluated 775 consecutive patients with symptoms suggestive of ACS; 
107 had normal ECG and 73 had minimal changes. Of these patients, 10% with a 
normal ECG had acute MI, and 6% with minimal changes developed acute MI (Slater 
et al., 1987).  
Even when non-diagnostic, ECG offers important risk-stratification information. 
For example, patients with confirmed MI but normal ECG have only 50% of the in-
hospital mortality rate of patients with diagnostic tracings (Anderson et al., 2007). 
STEMI diagnosis depends upon the presence of characteristic ECG findings: 
 New-onset STE higher than or equal to 1 mm (≥ 0.1 mV) in at least two 
contiguous leads 
 Appearance of presumably new left bundle branch block (LBBB) 
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Diagnosis of UA/NSTEMI depends on the presence of particular ECG features, as 
following: 
 ST-segment depression greater than 0.5 mm (> 0.05 mV) 
 Symmetrical T-wave inversion greater than 0.2 mV in precordial leads.  
1.2.4.2 Biochemical Cardiac Markers 
Along with clinical features and ECG, cardiac biomarker measurements are now 
considered a cornerstone in the assessment of patients suspected of ACS. Actually, a 
class I recommendation from the guidelines of the National Academy of Clinical 
Biochemistry (NACB) reads as follows: “Biomarkers of myocardial necrosis should 
be measured in all patients who present with symptoms consistent with acute coronary 
syndromes” (Morrow et al., 2007). 
Biochemical markers provide a noninvasive means of determining whether MI 
has occurred; they also provide important prognostic information. When ischemia 
gives way to infarction, there is a loss of integrity of the myocardial cell membrane. A 
series of macromolecules are in turn released into the systemic circulation. Of these, 
the optimal biological marker for MI would be the one: highly specific to myocardium, 
rapidly released, and sufficiently persistent in the circulation to allow detection 
(Morrow et al., 2007). 
Based on compelling evidence, cardiac troponins are the markers that most 
closely meet these criteria, and hence have become fundamental to diagnosis of MI, 
and are used for guidance of therapy and intervention for patients presenting with signs 
and symptoms of ACS. They are useful in detecting MI in patients presenting with 
atypical histories and non-diagnostic ECGs. Troponin testing also provides valuable 
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information in terms of risk-stratifying patients with ACS. There appears to be a clear 
link between the quantity of troponin measured and subsequent risk of death (Antman 
et al., 1996). 
Troponin complex has three structural regulatory proteins, troponin T, troponin 
I, and troponin C. Troponin C isoforms exist in both smooth and cardiac muscle and 
therefore lack sufficient cardiac specificity for clinical use (Thygesen, Alpert, & 
White, 2007). 
Troponins appear in circulation after onset of complete coronary occlusion 
subsequent to myocardial necrosis, so several hours usually pass before release and 
detection in the bloodstream. While troponins I and T appear in the blood within 4 to 
6 hours after necrosis; troponin I levels stay elevated for 4 to 7 days, whereas troponin 
T levels remain raised for 10 to 14 days. A critically essential factor when using cardiac 
troponins is timing of blood sample collection. Current recommendations from 
American College of Emergency Physicians (ACEP) state that measurement is to be 
done upon admission, followed by serial sampling based on the clinical circumstances. 
For most patients, this includes sampling at hospital admission and again 6–9 hours 
later. This helps to confirm or exclude the diagnosis and may be useful in estimating 
infarct size (Fesmire et al., 2006). Guidance is that a maximal concentration of cardiac 
troponins exceeding the decision limit (99th percentile of values for reference control 
group) at least once within the first 24 hours after the acute event is sufficient to 
indicate myocardial necrosis consistent with MI (Morrow et al., 2007; Thygesen, 
Alpert, White, et al., 2007). 
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Before the era of troponin, CK-MB isoenzyme assay was considered the gold 
standard marker for MI diagnosis. CK-MB performs less well than the cardiac 
troponins in terms of both sensitivity and specificity for MI. Case reports show that 
histologically proven MI is present in patients presenting with ACS who have normal 
levels of CK-MB but elevated troponins (Pettijohn et al., 1997). Recent guidelines 
indicate that CK-MB “mass” measurements are the next best choice when cardiac 
troponin is not available (Morrow et al., 2007). 
CK-MB also begins rising in the six-hour range but returns to normal values at 
approximately 48 hours post-MI (Fesmire et al., 2006). As a result, if a patient is 
admitted with raised troponin and CK-MB serum levels and several days later 
experiences recurrent chest pain, troponin would be less sensitive to detecting new 
myocardial injury, since it would still be raised. Therefore, CK-MB measurements can 
be useful to indicate early reinfarction (Antman et al., 2000). 
Similarly to troponins, the diagnostic limit for CK-MB is set as the 99th 
percentile in a sex-specific reference control group. Taking into account the lower 
tissue specificity as compared with troponin, it is suggested that two consecutive 
measurements of CK-MB exceeding this decision limit be considered sufficient 
biochemical indication of MI (Morrow et al., 2007). 
Elevation of CK-MB level is directly correlated to mortality and risk of adverse 
outcomes in patients with non-STE ACS, and the increased risk starts with CK-MB 
levels just above normal (Zimmerman et al., 1999).  
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1.2.4.3 Risk Stratification of ACS Patients 
Estimated risk of mortality or short-term adverse outcomes, based on clinical 
characteristics, is challenging and imprecise. Over the last 10 years, the importance of 
early risk stratification has been universally acknowledged in practice guidelines, with 
a current AHA/ACC class 1A recommendation for risk stratification in the setting of 
non-STE ACSs (Anderson et al., 2007; Ranasinghe et al., 2011). 
Risk assessment is needed to guide triage and direct management strategy for 
patients with ACS (Anderson et al., 2011; Ranasinghe et al., 2011). Even in the setting 
of STEMI, where initial therapeutic options are well-established, patient risk 
characteristics have an influence on early therapeutic decision making (Morrow et al., 
2000). 
Risk stratification in ACS patients not presenting with STE is more complicated, 
because in-hospital outcomes for this group differs, with reported mortality rates of 0–
12%, reinfarction of 0–3%, and recurrent severe ischemia of 5–20% (Steg et al., 2002). 
Figure 1.1. Biochemical markers in suspected acute coronary syndrome 
Reprinted from McGraw-Hill Publishers: (Spinler & Denus, 2011), copyright (2011)  
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Several clinical risk-stratification scoring systems are now widely available, 
based on initial medical history, ECG, and laboratory tests which can predict mortality 
or recurrent cardiac events in patients with ACS. The most commonly used scoring 
systems include platelet glycoprotein IIb/IIIa in UA: Receptor Suppression Using 
Integrilin Therapy (PURSUIT) (Boersma et al., 2000), Fast Revascularization during 
Instability in Coronary Artery Disease (FRISC)  (Lagerqvist et al., 2005), 
Thrombolysis in Myocardial Infarction (TIMI) (Antman et al., 2000; Morrow et al., 
2000), and Global Registry of Acute Cardiac Events (GRACE) risk scores (Granger et 
al., 2003). All these scoring systems were obtained from randomised controlled trial 
populations, except the GRACE registry, which was derived from an international 
“real life” observational registry. 
1.2.4.3 (a) TIMI Risk Score for UA/NSTEMI 
Antman et al. designed a 7-point risk score validated as being a useful prognostic 
tool to predict risk of developing an adverse cardiac outcome (mortality, new or 
recurrent infarction, or severe recurrent ischemia needing revascularization) through 
14 days of presentation for patients with non-STE ACS (Antman et al., 2000; Pollack, 
Sites, Shofer, Sease, & Hollander, 2006). 
TIMI risk score was originated from the TIMI IIB trial database and has been 
validated in several other trials of UA/NSTEMI (Chase et al., 2006). The score 
composes of seven predictor variables, each worth 1 point. Thus, scores may range 
between zero and seven. In accordance with this score, patients are stratified into high-
risk (5–7 points), medium-risk (3–4 points), or low-risk (0–2 points) categories (see 
Table 1.2). Studies show that rates of adverse events increase significantly as TIMI 
risk score increases. Risks ranged from 2–5% with a score of 0/1, to more than 30–
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40% for a score of 6/7 (Owen & Diercks, 2009). Furthermore, TIMI risk score seems 
to be predictive of increasing benefit from certain therapies as risk rises (Antman et 
al., 2000; Cannon et al., 2001). 
Table1.2. TIMI risk score for UA / NSTEMI  
Variables Points 
 Age ≥ 65                                                                                           1 point 
 At least 3 risk factors  for CAD (dyslipidemia, HPT, DM, 
premature cardiovascular disease family history status) 
1 point 
 Known CAD (Myocardial infarction history, documented CAD 
> 50% stenosis)    
1 point 
 
 ST- segment deviation ≥ 0.5mm on ECG at presentation                1 point 
 At least 2 anginal events in last 24 hours                                         1 point 
 Use of anti-platelet agent (ASA) in last 7 days                                1 point 
 Elevated serum cardiac enzymes/markers                                       1 point 
      Total                                                                                                      0 – 7 
(Antman et al., 2000). 
1.2.4.3 (b) TIMI Risk Score for STEMI 
Morrow et al. developed a clinical risk score validated as a simple bedside 
integer score that may be applied to assess short-term mortality risk within 30 days of 
presentation for patients with STEMI (Morrow et al., 2000; Morrow et al., 2001). 
TIMI risk score for STEMI was derived from the InTIMI II trial database and is 
based on eight clinical risk indicators routinely available at hospital presentation. The 
total score for each patient is the summation of the points for each risk indicator present 
(range 0–14) (Morrow et al., 2001). 
Studies find that risks of all-cause mortality at 30 days increase significantly as 
TIMI risk score increases. Risks ranged from 0.8–4.4% with a score of 0/3, to 35.9% 
for a score of more than 10 (Morrow et al., 2001). 
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Table 1.3. TIMI risk score for STEMI  
Variables Points 
 Age ≥ 75                                                                                                3 points 
 Age 65 to 74                                                                                          2 points 
 Diabetes OR Hypertension OR history of angina (onset more than 2 
weeks ago) OR New onset angina (Less than 2 weeks)   
 1 points 
 Systolic BP <100 mmHg 3 points 
 Heart Rate > 100 beat per minute                                                         2 points 
 Killip II-IV                                                                                            2 points 
 Weight < 67 kg                                                                                      1 points 
 Anterior STE (Leads V1 to V4) OR Left Bundle Branch block (BBB)   1 points 
 Time to Treatment > 4 hours                                                                 1 points 
      Total                                                                                                      0 – 14 
(Morrow et al., 2001). 
 
1.2.5 Complications of Acute Coronary Syndrome  
Patients with a history of ACS are particularly susceptible to developing a wide 
range of complications. They have a risk of more than 20% of heart failure, myocardial 
reinfarction, stroke, and death within 5 years (Pattanayak & Gelfand, 2009). Other 
complications include cardiogenic shock, valvular dysfunction, ventricular and atrial 
arrhythmias, bradycardia, heart block, and venous thromboembolism (Fox et al., 2006; 
Spinler & Denus, 2011). In fact, around 60% of mortality from ACS occurs in patients 
with prior cardiac events (Vermeer & Bajorek, 2008). 
1.2.6 Management of Acute Coronary Syndrome  
Once a patient presents to hospital and is diagnosed with ACS, management 
serves two purposes: reducing the burden of disability and mortality after the attack, 
and minimizing risk of a recurrent ischemic event, referred to as secondary prevention. 
Acute treatment of ACS involves (1) immediate relief of ischemic chest discomfort 
during the acute attack, (2) early revascularization of the culprit coronary artery to 
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prevent infarct expansion (in case of acute MI) or total occlusion and MI (in case of 
UA), and (3) prevention of death, coronary artery reocclussion, or other complications. 
In the past 20 years, the management of ACS has advanced and undergone 
numerous changes. Pharmacotherapy of ACS has evolved to include combinations of 
anti-ischemic therapy, fibrinolytics, and antithrombotics. In addition, pharmaco-
therapy has incorporated with reperfusion therapy and restoration of blood supply to 
the infarct-related artery through interventional techniques such as percutaneous 
coronary intervention (PCI) and/or coronary artery bypass graft surgery (CABG) 
(Spinler & Denus, 2011). 
1.2.6.1 Anti-ischemic Therapy 
Anti-ischemic treatments primarily address the demand side of the myocardial 
ischemia equation. Treatments commonly used currently include oxygen, nitrates, 
morphine, β-blockers, calcium channel blockers, and angiotensin converting enzyme 
inhibitors (ACEI). These treatments are described in greater detail in the following 
subsections. 
1.2.6.1 (a) Oxygen 
Oxygen administration is frequently recommended in international guidelines 
for all patients with suspected myocardial ischemia; nonetheless, there is controversy 
about its safety and efficacy. A systematic review, including non-randomised studies, 
does not confirm that supplemental oxygen decreases acute myocardial ischemia; in 
fact, some evidence suggests it may actually aggravate ischemia (Nicholson, 2004).  
The ACC recommendations suggest administering oxygen only to those patients with 
a peripheral oxygen saturation of less than 90%, although this cut-off is apparently 
